| DHA 12‐LOX‐derived oxylipins regulate platelet activation and thrombus formation through a PKA‐dependent signaling pathway A Yamaguchi, L Stanger, CJ Freedman, M Standley, T Hoang, R Adili, ... Journal of Thrombosis and Haemostasis 19 (3), 839-851, 2021 | 25 | 2021 |
| Supplementation with omega‐3 or omega‐6 fatty acids attenuates platelet reactivity in postmenopausal women A Yamaguchi, L Stanger, JC Freedman, A Prieur, R Thav, J Tena, ... Clinical and Translational Science 15 (10), 2378-2391, 2022 | 6 | 2022 |
| Bioactive lipid regulation of platelet function, hemostasis, and thrombosis L Stanger, M Holinstat Pharmacology & Therapeutics, 108420, 2023 | 5 | 2023 |
| Antiplatelet strategies: past, present, and future L Stanger, A Yamaguchi, M Holinstat Journal of Thrombosis and Haemostasis 21 (12), 3317-3328, 2023 | 3 | 2023 |
| The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor L Stanger, A Yamaguchi, P Yalavarthi, S Lambert, D Gilmore, ... Blood 142 (18), 1556-1569, 2023 | 3 | 2023 |
| Experimental venous thrombus resolution is driven by IL-6 mediated monocyte actions AT Obi, SB Sharma, MA Elfline, CE Luke, AR Dowling, Q Cai, AS Kimball, ... Scientific Reports 13 (1), 3253, 2023 | 3 | 2023 |
| Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice R Adili, M Jackson, L Stanger, X Dai, M Li, BX Li, M Holinstat Clinical and Applied Thrombosis/Hemostasis 27, 10760296211018510, 2021 | 2 | 2021 |
| CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists L Stanger, P Yalavarthi, S Lambert, A Rickenberg, K Goerger, D Gilmore, ... Blood 142, 1188, 2023 | | 2023 |
| HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding L Stanger, M Holinstat, S Lambert, P Yalavarthi, N Bergh, B Dahlof Blood 142, 1195, 2023 | | 2023 |
| HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner M Holinstat, L Stanger, S Lambert, B Dahlof, N Bergh European Heart Journal 44 (Supplement_2), ehad655. 2857, 2023 | | 2023 |
| Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis L Stanger, S Lambert, A Yamaguchi, P Yalavarthi, B Dahlof, N Bergh, ... European Heart Journal 44 (Supplement_2), ehad655. 2856, 2023 | | 2023 |
| Investigating the catalytic efficiency of C22-Fatty acids with LOX human isozymes and the platelet response of the C22-oxylipin products M Tran, L Stanger, S Narendra, M Holinstat, TR Holman Archives of Biochemistry and Biophysics 747, 109742, 2023 | | 2023 |
| The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor A Yamaguchi, S Lambert, L Stanger, P Yalavarthi, A Rickenberg, A White, ... Arteriosclerosis, Thrombosis, and Vascular Biology 43 (Suppl_1), A122-A122, 2023 | | 2023 |
